Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
A Stanford-led study found that tau may drive neurodegeneration by disrupting mitochondrial electron flow, creating reactive oxygen species, cellular stress and inflammation. The work suggests a new way to intervene beyond simply targeting tau aggregates.
A Stanford-led study found that tau may drive neurodegeneration by disrupting mitochondrial electron flow, creating reactive oxygen species, cellular stress and inflammation. The work suggests a new way to intervene beyond simply targeting tau aggregates.
READ MORE
After two previous rejections, Replimune’s advanced melanoma immunotherapy secures FDA approval, capping years of regulatory twists and strong oncologist support.
The FDA has approved a ground-breaking narcolepsy drug from Takeda, signaling a huge step forward for patients and the broader drug class.
Pathos AI has made headlines with two major cancer deals involving AstraZeneca and China’s Alphamab. While specific financial details remain under wraps for the AstraZeneca pact, Pathos could pay over $2 billion for a late-stage breast cancer asset developed by Alphamab.
Apnimed’s successful $192 million IPO propels the company toward the launch of Oxnimbi, which could become the first FDA-approved oral medication for obstructive sleep apnea if regulatory review proceeds as planned.
Early clinical findings from ProMIS Neurosciences reveal potential progress toward a safer amyloid-clearing drug for Alzheimer’s disease, addressing a long-standing challenge of managing adverse effects.
Alpha-1 antitrypsin deficiency, once viewed as an untreatable and niche condition, is now the center of intense biotech competition with gene-editing breakthroughs, patent disputes, and a US-China rivalry shaping the landscape.
Otsuka Pharmaceutical’s ADHD drug Simtriyo, now FDA approved, marks the first norepinephrine, dopamine, and serotonin reuptake inhibitor—a new class that experts estimate could address over $600M in unmet needs and reshape the competitive ADHD market.
Scribe Therapeutics’ public debut with a $129M IPO represents a milestone for early-stage gene editing biotech firms and a bellwether for the wider CRISPR innovation landscape.
GSK achieves a significant milestone as Jideytro, acquired from Nuvalent in a $10.6 billion deal, receives FDA approval for advanced non-small cell lung cancer with ROS1 alterations.
Summit Therapeutics and Akeso present new data for ivonescimab, addressing critical questions about its application in Western markets, though statistical significance of results remains unconfirmed.
